HPV is the English abbreviation of human papillomavirus, which is a type of double-stranded circular DNA virus. At present, more than 130 types of HPV have been separated, which mainly infect the human epidermis and mucosal tissues, which can cause varying degrees of harm to the human body, such as cancer, miscarriage, infertility, and termination of pregnancy.

Cervical cancer ranks second in the female population. More than 98% is caused by HPV infection and is the only cancer with a clear cause. The famous movie stars Anita Mui and Li Yuanyuan both suffered from cervical cancer and died young, making people sigh.

Eliminating HPV to prevent the occurrence and development of cervical cancer has become a consensus in the medical community. But so far, traditional treatment methods and HPV vaccines are helpless against existing HPV infections. With the continuous advancement of science and technology, ACTL targeted cellular immune technology has overcome this worldwide problem and has become an effective treatment for killing HPV and eliminating HPV infection.

ACTL technology is a precision treatment that combines oncology, molecular biology, and immunology with an internationally leading level. It has won a scientific and technological progress award and a national invention patent. It can kill HPV in a targeted and specific manner, effectively treat HPV infection and its related precancerous lesions and early, middle and late cervical cancer, bringing good news to women.

Because ACTL technology has achieved good results in the treatment of HPV infection, precancerous lesions and cervical cancer, it has produced a good reputation among gynecologists, oncologists and female patients.

At the request of all sectors of society, in order to allow more female sisters to receive timely treatment and solve their troubles, Huiying Memorial Foundation, several domestic hospitals and Shenzhen Yishi Kangning Biotechnology Co., Ltd. jointly launched a free ACTL technology to treat HPV. Infection/precancerous lesion/cervical cancer send love volunteer activity. The top 10 applicants who are eligible for treatment are free of charge. Experts will closely observe the entire treatment process, make an objective evaluation of the curative effect, and give follow-up guiding opinions.

>>>>
The activity rules are as follows
Time: From May 15, 2017, until the quota is full.

>>>>
What are the requirements for participating in this support plan?
Patients must have been diagnosed with high-risk HPV infection (such as HPV 16, 18, etc.)/precancerous lesions and cervical cancer caused by high-risk HPV infection.
The patient has not undergone surgery to remove the uterus.


>>>>

ways of registration
Patients can bring HPV examination reports, pathology reports, imaging reports of recent progress, detailed treatment history, medical history and other information to contact Shenzhen Yishi Kangning Biotechnology Co., Ltd. After the hospital and Huiying Foundation review, the staff will Inform you in time whether you meet the requirements for entry.

Company Address: 16th Floor, Unit A1, Kexing Science Park, No. 15, Keyuan Road, Nanshan District, Shenzhen

Contact: Zhang Wenli, Wang Hongliang

Contact number: 0755-86680658

Email: zhang.wenli@immuclin.com, wang.hongliang@immuclin.com

WeChat ID: ACTL-HPV

>>>>
How effective is ACTL treatment?



Case number one

The patient Zhang, female, was tested positive for HPV16 and HPV18 in her cervical HPV examination in January 2015. In the absence of other treatment, the patient received ACTL treatment. After 7 treatments, the HPV infection disappeared, and the patient was re-examined in mid-November 2015. The result indicated that "no papillomavirus infection was seen."



Pre-treatment examination prompts: HPV16 and HPV18 positive


Patient Li, female, cervical HPV test showed that HPV58 is positive, CIN stage II, the doctor has recommended surgery to remove the cervix. The patient wanted conservative treatment, so he accepted ACTL treatment. After 3 treatments, the patient was re-examined, and the test report indicated "no obvious lesions".

治疗前检查提示：HPV58型阳性Checkup before treatment prompts: HPV58 positive

Inspection after treatment revealed: no papillomavirus infection

Case two

Patient Li, female, cervical HPV test showed that HPV58 is positive, CIN stage II, the doctor has recommended surgery to remove the cervix. The patient wanted conservative treatment, so he accepted ACTL treatment. After 3 treatments, the patient was re-examined, and the test report indicated "no obvious lesions".



Inspection after treatment showed that HPV58 type changed from positive to negative

>>>>
Abstract of literature on ACTL used to treat HPV infection/cervical cancer